ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Total Liabilities
Everything the company owes to creditors and other parties.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 95.4% from a year ago
Total liabilities stood at $25.32M at the end of Q1 FY2026, up 95.4% from a year earlier and down 2.4% from the prior quarter. Over 3 fiscal years it compounded at +45.8% a year.
Context
- Total liabilities amounted to 7.2% of total assets at the end of Q1 FY2026, up 1.2 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +95.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 25.95M USD
- Year-over-year change
- +50.1%
- 4-year CAGR
- +94.4%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.95M | +50.1% |
| FY2024 | 2024-12-31 | 17.29M | +46.5% |
| FY2023 | 2023-12-31 | 11.8M | +41.0% |
| FY2022 | 2022-12-31 | 8.37M | +360.5% |
| FY2021 | 2021-12-31 | 1.82M | — |
Total Liabilities vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's Mar 2026 total liabilities of $25.32M is the 9th highest of the 11 companies compared; the peer median is $87.64M.
- Its year-over-year change of +95.4% is the highest of 11, against a peer median of +7.1%.
- Total liabilities amounts to 7.2% of total assets for AVBP, versus a peer median of 23.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jul 2026 | $650.47M | +0.9% | +5.4% | 26.1% | |
| Dec 2025 | $501.84M | -0.1% | +8.5% | 28.6% | |
| Jun 2026 | $490.64M | +78.9% | +156.8% | 65.9% | |
| Jun 2026 | $467.76M | +25.6% | +37.8% | 43.5% | |
| Mar 2026 | $93.08M | +21.7% | +30.9% | 9.0% | |
| Sep 2026 | $82.2M | +13.4% | -11.7% | 8.2% | |
| Mar 2026 | $64.28M | -35.1% | -24.6% | 33.4% | |
| Mar 2026 | $28.62M | -17.6% | -8.8% | 21.5% | |
| Mar 2026 | $25.32M | +95.4% | +45.8% | 7.2% | |
| Mar 2026 | $24.47M | +22.7% | +41.0% | 5.9% | |
| Mar 2026 | $21.21M | -8.3% | -1.7% | 4.9% | |
| Peer median (excluding AVBP) | $87.64M | +7.1% | +7.0% | 23.8% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 37.28M | 163.37M | 150.39M | 74.29M | 45.54M |
| Short-term Investments | 0 | 0 | 0 | 144.57M | 267.28M |
| Net Receivables | 0 | 0 | 0 | 500K | 60K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.64M | 18.92M | 9.21M | 7.21M | 20.02M |
| Total Current Assets | 42.95M | 182.62M | 159.97M | 226.98M | 332.9M |
| Property, Plant & Equipment (Net) | 0 | 139K | 291K | 154K | 13K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 47.68M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 87K | 72K | 2.84M | 126K | 259K |
| Total Non-current Assets | 87K | 211K | 3.13M | 47.96M | 272K |
| Total Assets | 43.04M | 182.83M | 163.1M | 274.94M | 333.17M |
| Account Payables | 293K | 3.09M | 4.53M | 3.78M | 5.93M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 4.16M | 6.55M |
| Total Current Liabilities | 1.82M | 8.36M | 11.62M | 17.27M | 25.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 11K | 177K | 14K | 0 |
| Total Liabilities | 1.82M | 8.37M | 11.8M | 17.29M | 25.95M |
| Common Stock | 0 | 0 | 0 | 3K | 4K |
| Retained Earnings | (51.61M) | (88.51M) | (157.85M) | (238.33M) | (404.64M) |
| Accumulated OCI | (2K) | 0 | 0 | (211K) | 14K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.22M | 174.46M | 151.3M | 257.65M | 307.22M |
| Total Debt | 0 | 139K | 317K | 176K | 14K |
| Net Debt | (37.28M) | (163.23M) | (150.07M) | (74.12M) | (45.53M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.